Time filter

Source Type

Aguera-Ortiz L.,Institute Investigacion Hospital Universitario 12 Of Octubre | Cuervo J.,LA SER Group | Medina E.,Astrazeneca | Diaz-Cuervo H.,LA SER Group | Maurino J.,Astrazeneca
Actas Espanolas de Psiquiatria

Objective: To adapt the CUDOS scale (Clinically Useful Depression Outcome Scale) into Spanish and to test its psychometrical properties in a sample of patients with major depressive disorder (MDD). Methods: A two-step cross-sectional, multicenter validation study was conducted (linguistic adaptation into Spanish and psychometric validation). The study evaluated patients attended in Primary Care with a MDD diagnosis within the last 3 months (DSM-IV TR criteria). The following scales were administered: CUDOS, PRIME-MD (Primary Care Evaluation of Mental Disorders), HAMD-17 (Hamilton Depression Rating Scale), SOFAS (Social and Occupational Functioning Assessment Scale), SF-36 (Physical-PCS- and Mental-MCS-Component Summaries), and the CGI-S &PGI-S (Clinical Global Impression for Severity of Illness scales for clinicians and patients, respectively). Feasibility, reliability, and validity of the Spanish version were assessed. Results: In the validation study, 305 MDD patients (69.5% female) with a mean age (standard deviation-SD-) of 51.75(15.53) were included. Mean completion time was 4.47(2.4) minutes. Floor or ceiling effects were found in less than 1%of the case scores. Internal consistency was adequate (Cronbach's α= 0.88). Pearson correlation coefficients with CUDOS were:-0.42 (SOFAS), 0.45 (HAMD-17), -0.22 (PCS), -0.65 (MCS);all p<0.001. The CUDOS properly discriminated among clinical severity levels (p<0.03). Conclusions: The adapted Spanish version of the CUDOS shows adequate psychometric properties as an evaluation instrument of major depression from the patient's perspective. Source

Jurado-Barba R.,Institute Investigacion Hospital Universitario 12 Of Octubre | Jurado-Barba R.,Research Center Biomedica En Red Of Salud Mental | Jurado-Barba R.,Hospital Universitario 12 Of Octubre | Morales-Munoz I.,Institute Investigacion Hospital Universitario 12 Of Octubre | And 12 more authors.
Psychiatry Research

Disruption of prepulse inhibition of the startle response (PPI) has been widely identified in patients with schizophrenia, as well as impairment in many domains of cognitive functioning. However, there is some controversy regarding the relationship between PPI and the different neuropsychological tasks assessing inhibition. This controversy may be due to the influence of other variables, such as substance abuse. We aimed to determine whether differences in inhibition in schizophrenia subjects were related to their pattern of substance use and whether there was a correlation between the changes in each process. PPI and neuropsychological functioning were studied in three groups of subjects with schizophrenia (N= 73): tobacco dependents (ToD; n= 22), multiple substance abusers (MSUD; n= 31) and non-substance abusers (non-SUD; n= 20). All subjects were assessed using PPI and neuropsychological tests (Stroop and Wisconsin Card Sorting Test [WCST]). ToD showed better pre-attentive inhibitory function compared to the other two groups, and MSUD showed lower resistance to interference. Furthermore, significant correlations were found between PPI, Stroop, and WCST. Our data suggest that there is a relationship between the different tasks assessing inhibition in schizophrenia, being affected by substance abuse history. We also found differences in inhibition capacity depending on substance abuse in patients with schizophrenia. © 2011 Elsevier Ltd. Source

Serrano M.,Institute Investigacion Hospital Universitario 12 Of Octubre | Martinez-Flores J.A.,Institute Investigacion Hospital Universitario 12 Of Octubre | Castro M.J.,Institute Investigacion Hospital Universitario 12 Of Octubre | Garcia F.,Institute Investigacion Hospital Universitario 12 Of Octubre | And 10 more authors.
Journal of Immunology Research

IgA anti-beta-2-glycoprotein I (aB2GPI) antibodies have been related to vascular pathology in the general population and mainly in hemodialyzed patients (prevalence 33%) in whom an elevated incidence of thrombosis and mortality is found. In this paper we have studied the presence of IgA aB2GPI antibodies at pretransplant and their evolution after transplantation with a cross-sectional-based follow-up study of a cohort of 288 endstage renal disease (ESRD) patients treated with kidney transplantation. Pretransplant IgA aB2GPI levels were elevated 31.7 ± 4.2 U/mL without differences in age or type of dialysis. Patients with different etiologies of ESRD showed higher levels of IgA aB2GPI than blood donors, except the groups of non-IgA glomerular disease and systemic erythematosus lupus, whose nonsignificant differences were observed. IgA aB2GPI antibodies dropped immediately after transplantation (10.7 ± 1.0 U/mL, P < 0.0001), coinciding with a high degree of immunosuppression, and remained significantly lower than that observed in pretransplant status. Prevalence of patients with elevated antibodies was also less in transplanted patients (8.9% versus 30.4%, P < 0.0001). Among, positivity for IgA aB2GPI was higher than in patients who had received their first transplant that those were retransplanted. This finding could have important clinical implications and can suggest new therapeutic strategies in patients with IgA aB2GPI antibodies. © 2014 Manuel Serrano et al. Source

Ruiz-Garcia R.,Institute Investigacion Hospital Universitario 12 Of Octubre | Serrano M.,Institute Investigacion Hospital Universitario 12 Of Octubre | Angel Martinez-Flores J.,Institute Investigacion Hospital Universitario 12 Of Octubre | Mora S.,Institute Investigacion Hospital Universitario 12 Of Octubre | And 7 more authors.
Journal of Immunology Research

Seronegative antiphospholipid syndrome (SNAPS) is an autoimmune disease present in patients with clinical manifestations highly suggestive of Antiphospholipid Syndrome (APS) but with persistently negative consensus antiphospholipid antibodies (a-PL). IgA anti-β2 Glycoprotein I (aB2-GPI) antibodies are associated with APS. However, they are not currently considered to be laboratory criteria due to the heterogeneity of published works and the use of poor standardized diagnostic systems. We have aimed to assess aPL antibodies in a group of patients with clinical manifestations of APS (C-APS) to evaluate the importance of the presence of IgA aB2GPI antibodies in APS and its relation with other aPL antibodies. Only 14% of patients with C-APS were positive for any consensus antibody, whereas the presence of isolated IgA aB2GPI antibodies was found in 22% of C-APS patients. In patients with arterial thrombosis IgA aB2GPI, antibodies were the only aPL antibodies present. Serologic profile in primary APS (PAPS) is different from systemic autoimmune disorders associated APS (SAD-APS). IgA aB2GPI antibodies are more prevalent in PAPS and IgG aB2GPI antibodies are predominant in SAD-APS. The analysis of IgA aB2GPI antibodies in patients with clinical manifestations of PAPS might avoid underdiagnosed patients and provide a better diagnosis in patients with SAD-APS. Laboratory consensus criteria might consider including analysis of IgA aB2GPI for APS diagnosis. © 2014 Raquel Ruiz-García et al. Source

Martinez-Flores J.A.,Institute Investigacion Hospital Universitario 12 Of Octubre | Serrano M.,Institute Investigacion Hospital Universitario 12 Of Octubre | Perez D.,Institute Investigacion Hospital Universitario 12 Of Octubre | Lora D.,Institute Investigacion Hospital Universitario 12 Of Octubre | And 5 more authors.
Journal of Immunological Methods

Patients with antiphospholipid syndrome (APS) have a hypercoagulable condition associated with the presence of antiphospholipid autoantibodies (aPL). Consensus antibodies for diagnosis are lupus anticoagulant, anti-beta2 glycoprotein I (B2GPI) and anticardiolipin (IgG or IgM). Circulating immunocomplexes (CIC) of B2GPI associated with IgM or IgG were reported.Isolated IgA aB2GPI antibodies have achieved high diagnostic value although specific CIC of B2GPI bounded to IgA (B2A-CIC) has still not been described. CIC detection assays are mainly based on interaction with complement and are not appropriate to detect B2A-CIC because IgA does not fix complement using the classical pathway. Patients and methods: Sera from healthy blood donors (N = 247) and from patients with thrombosis background and isolate positive for IgA aB2GPI (N = 68) were studied in a case-control study. Two methods were applied, these being a capture ELISA to quantify specific B2A-CIC and quantification of total IgA anti-B2GPI after dissociating CIC. Results: B2A-CIC values in APS-patients were 19.27 ± 2.6. AU vs 6.1. ±0.4. AU in blood donors (p. <0.001). There were 36.4% B2A-CIC positive patients (cutoff 21. AU) versus 5.5% in blood donors (p. <0.001). Dissociated IgA aB2GPI levels (total IgA aB2GPI) were 146.8 ± 10.8. IU/mL in patients vs. 22.4. IU/mL in controls (p. <0.001). B2A-CIC was independent of B2GPI and autoantibodies IgA aB2GPI serum levels. Conclusion: B2A-CIC can be identified and quantified in an easy and reproducible manner using two complement-independent methods. The use of these tests in prospective studies will allow better understanding of the prognosis and outcome of patients. © 2015 Elsevier B.V. Source

Discover hidden collaborations